Premium
Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review
Author(s) -
Moore Malcolm
Publication year - 1996
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19960801)78:3+<633::aid-cncr8>3.0.co;2-b
Subject(s) - medicine , gemcitabine , carcinoma , pancreatic carcinoma , oncology , general surgery , pancreatic cancer , cancer
BACKGROUND In early phase II trials in advanced pancreatic cancer, gemcitabine demonstrated modest antitumor activity. The investigators in these studies reported that gemcitabine should be studied further in view of the degree and frequency of symptomatic improvement observed, the durability of some of the remissions, and the favorable toxicity profile. METHODS In order to quantify such symptomatic improvement, a rigorous endpoint of Clinical Benefit was developed that incorporated measures including pain intensity, analgesic consumption and performance status, which have been shown to be reliable and valid endpoints in other studies. RESULTS Two trials have been conducted using this methodology in patients with advanced pancreatic carcinoma. CONCLUSIONS The results of these studies suggest that gemcitabine is the first cytotoxic agent with any meaningful impact on survival and disease‐related symptoms in advanced pancreatic adenocarcinoma. The degree of improvement seen is one which patients with cancer often consider to be most important. Further studies will be required to define more fully the role of gemcitabine in the treatment of pancreatic cancer. Cancer 1996;78:633‐8.